Skip to content
10-Q

Quarterly Report

INVIVO THERAPEUTICS HOLDINGS CORP.

0001558370-22-016639

← back to feed
Filed
Nov 7, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Nov 4, 2022 1.91M sh
Cash And Equivalents Q3 2022 · Sep 30, 2022 $10.6M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $19.03M
Current Liabilities Q3 2022 · Sep 30, 2022 $2.5M
Current Liabilities Q3 2022 · Dec 31, 2021 $2.61M
Total Liabilities Q3 2022 · Sep 30, 2022 $3.26M
Total Liabilities Q3 2022 · Dec 31, 2021 $3.66M
Current Assets Q3 2022 · Sep 30, 2022 $11.56M
Current Assets Q3 2022 · Dec 31, 2021 $19.14M
Total Assets Q3 2022 · Sep 30, 2022 $13.36M
Total Assets Q3 2022 · Dec 31, 2021 $21.77M
Eps Diluted Q3 2022 · Sep 30, 2022 −$1.98
Eps Diluted Q3 2022 · Sep 30, 2021 −$1.79
Eps Diluted Q3 2022 · Sep 30, 2021 −$5.47
Shares Diluted Q3 2022 · Sep 30, 2021 1.37M sh
Shares Diluted Q3 2022 · Sep 30, 2021 1.28M sh
Capex Q3 2022 · Sep 30, 2021 $18K
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$6.84M
Stockholders Equity Q3 2022 · Sep 30, 2021 $20.94M
Stockholders Equity Q3 2022 · Jun 30, 2021 $23.31M
Stockholders Equity Q3 2022 · Mar 31, 2021 $25.52M
Stockholders Equity Q3 2022 · Dec 31, 2020 $19.19M
Eps Basic Q3 2022 · Sep 30, 2021 −$1.79
Eps Basic Q3 2022 · Sep 30, 2021 −$5.47
Sga Expense Q3 2022 · Sep 30, 2021 $1.34M
Sga Expense Q3 2022 · Sep 30, 2021 $3.93M
Rd Expense Q3 2022 · Sep 30, 2021 $1.12M
Rd Expense Q3 2022 · Sep 30, 2021 $3.06M
Net Income Q3 2022 · Sep 30, 2021 −$2.45M
Net Income Q3 2022 · Sep 30, 2021 −$6.98M
Net Income Q3 2022 · Jun 30, 2021 −$2.31M
Net Income Q3 2022 · Mar 31, 2021 −$2.22M
Operating Income Q3 2022 · Sep 30, 2021 −$2.45M
Operating Income Q3 2022 · Sep 30, 2021 −$6.99M